Glomerulonephritis clinical trials

Explore recruiting glomerulonephritis clinical trials.

Recruiting glomerulonephritis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Glomerulonephritis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Safety Outcomes Post Kidney Biopsy – randomized clinical Evaluation of Efficacy of Desmopressin

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Study of immunological activity after personalized immunomodulatory therapy regulating the Th17 pathway in patients with extramembranous glomerulonephritis

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Austria, Netherlands, Italy, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Impact of dapagliflozin for the regulation of immunological activity in Membranous Nephropathy

France

Phase II and Phase III (Integrated) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled Study of Intravenously Administered ALE.F02 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Renal Sparing in Antineutrophil Cytoplasmic Antibody Associated Vasculitis With Rapidly Progressive Glomerulonephritis

Czechia, Germany, Italy, Spain, Denmark, France +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplant Recurrence of C3G or IC‑MPGN

Netherlands, Austria, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Glomerulonephritis trials by city

Glomerulonephritis in Toronto Glomerulonephritis in Vancouver Glomerulonephritis in Montreal Glomerulonephritis in Calgary Glomerulonephritis in Edmonton Glomerulonephritis in Ottawa Glomerulonephritis in Winnipeg Glomerulonephritis in Quebec City Glomerulonephritis in Hamilton Glomerulonephritis in Kitchener Glomerulonephritis in London Glomerulonephritis in Halifax Glomerulonephritis in New York Glomerulonephritis in Los Angeles Glomerulonephritis in Chicago Glomerulonephritis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease